Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a 0,1,6 Mth Schedule in Healthy Female Subjects Aged 10-14 Yrs

NCT00290277 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00290277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00290277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a 0,1,6 Mth Schedule in Healthy Female Subjects Aged 10-14 Yrs
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2005
Completion date
August 31, 2006
Enrollment
300 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

infections, papillomavirus